A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **

Manish A  Shah; Eduardo Patricio Yanez Ruiz; Gyorgy Bodoky; Alexander Starodub; David Cunningham; Desmond Yip; Zev A  Wainberg; Johanna Bendell; Dung Thai; Pankaj Bhargava; Jaffer A Ajani

doi:10.1200/JCO.2019.37.4_suppl.4

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **

Manish A Shah, Eduardo Patricio Yanez Ruiz, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A Wainberg, Johanna Bendell, Dung Thai, Pankaj Bhargava, Jaffer A Ajani

School of Medicine and Psychology

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Journal	Meeting Abstract 2019 Gastrointestinal Cancers Symposium
Volume	37
Issue number	4
DOIs	https://doi.org/10.1200/JCO.2019.37.4_suppl.4
Publication status	Published - 2019
Event	2019 Gastrointestinal Cancers Symposium - San Francisco, California Duration: 1 Jan 2019 → … https://www.adacap.com/2019-gastrointestinal-cancers-symposium/

Access to Document

10.1200/JCO.2019.37.4_suppl.4

Cite this

Shah, M. A., Ruiz, E. P. Y., Bodoky, G., Starodub, A., Cunningham, D., Yip, D., Wainberg, Z. A., Bendell, J., Thai, D., Bhargava, P., & Ajani, J. A. (2019). A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **. Meeting Abstract 2019 Gastrointestinal Cancers Symposium, 37(4). https://doi.org/10.1200/JCO.2019.37.4_suppl.4

Shah, Manish A ; Ruiz, Eduardo Patricio Yanez ; Bodoky, Gyorgy et al. / A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **. In: Meeting Abstract 2019 Gastrointestinal Cancers Symposium. 2019 ; Vol. 37, No. 4.

@article{e082f112410a4e38b599659406633572,

title = "A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **",

author = "Shah, {Manish A} and Ruiz, {Eduardo Patricio Yanez} and Gyorgy Bodoky and Alexander Starodub and David Cunningham and Desmond Yip and Wainberg, {Zev A} and Johanna Bendell and Dung Thai and Pankaj Bhargava and Ajani, {Jaffer A}",

year = "2019",

doi = "10.1200/JCO.2019.37.4_suppl.4",

language = "English",

volume = "37",

journal = "Meeting Abstract 2019 Gastrointestinal Cancers Symposium",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "4",

note = "2019 Gastrointestinal Cancers Symposium ; Conference date: 01-01-2019",

url = "https://www.adacap.com/2019-gastrointestinal-cancers-symposium/",

}

Shah, MA, Ruiz, EPY, Bodoky, G, Starodub, A, Cunningham, D, Yip, D, Wainberg, ZA, Bendell, J, Thai, D, Bhargava, P & Ajani, JA 2019, 'A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **', Meeting Abstract 2019 Gastrointestinal Cancers Symposium, vol. 37, no. 4. https://doi.org/10.1200/JCO.2019.37.4_suppl.4

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **. / Shah, Manish A ; Ruiz, Eduardo Patricio Yanez; Bodoky, Gyorgy et al.
In: Meeting Abstract 2019 Gastrointestinal Cancers Symposium, Vol. 37, No. 4, 2019.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **

AU - Shah, Manish A

AU - Ruiz, Eduardo Patricio Yanez

AU - Bodoky, Gyorgy

AU - Starodub, Alexander

AU - Cunningham, David

AU - Yip, Desmond

AU - Wainberg, Zev A

AU - Bendell, Johanna

AU - Thai, Dung

AU - Bhargava, Pankaj

AU - Ajani, Jaffer A

PY - 2019

Y1 - 2019

U2 - 10.1200/JCO.2019.37.4_suppl.4

DO - 10.1200/JCO.2019.37.4_suppl.4

M3 - Meeting Abstract

SN - 0732-183X

VL - 37

JO - Meeting Abstract 2019 Gastrointestinal Cancers Symposium

JF - Meeting Abstract 2019 Gastrointestinal Cancers Symposium

IS - 4

T2 - 2019 Gastrointestinal Cancers Symposium

Y2 - 1 January 2019

ER -

Shah MA, Ruiz EPY, Bodoky G, Starodub A, Cunningham D, Yip D et al. A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). **. Meeting Abstract 2019 Gastrointestinal Cancers Symposium. 2019;37(4). doi: 10.1200/JCO.2019.37.4_suppl.4